Found 101 clinical trials
Human Laboratory Screening of Semaglutide for Alcohol Use Disorder
, making it a key priority to advance therapies for concurrent AUD and cigarette smoking. Recent preclinical evidence indicates that glucagon-type peptide-1, an incretin hormone, impacts both alcohol and
- 0 views
- 27 Oct, 2022
- 1 location
Endoscopic Sleeve Gastroplasty for Obesity and Microbiota Randomized Trial
-Alcoholic Fatty Liver Disease (NAFLD) Non- Alcoholic-Steato-Hepatitis (NASH) Satiety Gut microbiota Exploratory endpoints: Gut hormones e.g. glucagon
- 0 views
- 17 Feb, 2021
- 1 location
Restoration of Hypoglycemia Awareness With Home-based High Intensity Interval Training
hypoglycemia. The educational program will consist of two education sessions on avoidance of hypoglycemia, causes of hypoglycemia, treatment (e.g. glucagon) of hypoglycemia, how to better recognize
- 0 views
- 29 Aug, 2021
- 1 location
Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease (GLIMP)
clinical outcome in patient with CKD. Insulin resistance plays a critical role in skeletal muscle wasting and ectopic fat deposition. Glucagon-like peptide-1 receptor agonists (GLP-1RA) decrease ectopic
- 0 views
- 18 Apr, 2022
- 1 location
Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D) (Dapa-Stress)
Dapagliflozin influences glucagon levels during insulin withdrawal and how this is associated with the time course of DKA development.
- 0 views
- 04 Oct, 2022
- 1 location
Interest of GLP1 Analogues in Overweight Type 2 Diabetic Patients With Chronic Inflammatory Bowel Disease (DiagMICI)
(including type 2 diabetes and obesity), would involve metabolites in the gut that are modulated by the gut microbiota. Glucagon-Like Peptide 1 (aGLP1) analogues are a new class of injectable
- 0 views
- 21 Mar, 2022
- 1 location
Transport of Satiety Factors Into the CSF
the appetite-suppressing hormones (e.g. Leptin, Insulin, GLP 1 and Glucagon) reach the liquor and so the central nervous system. In order to understand the temporal sequence, simultaneous
- 0 views
- 10 Apr, 2022
- 1 location
Efficacy and Safety of Sitagliptin Plus Glargine in Comparison to Glargine Alone on Glycemic Control in Non-critically Ill Hospitalized Patients (SITAGLAR-H)
vein, dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of oral glucose lowering agents that reduce the breakdown of endogenous glucagon-like peptide-1 (GLP-1) stimulating insulin secretion in a
- 0 views
- 21 Oct, 2022
Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients
metabolic actions in T2DM. They potentiate insulin-stimulated insulin secretion from the beta cell , inhibit glucagon secretion from the alpha cells and inhibit appetite and promote weight loss. Together
- 0 views
- 25 Jan, 2021
- 1 location
Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients (SAMAS)
glycaemic control, the choice of antidiabetic drugs is also important. Large-scale research has shown that certain glucagon-like peptide (GLP-1) receptor agonists, in addition to improving the regulation of
- 0 views
- 08 Jun, 2022
- 1 location